P2.09. Real World Analysis Afatinib as a First Line Treatment Patients with Advanced Stage Non-small Cell Lung Cancer Harboring Uncommon EGFR Mutations - PDF(Abstract)
Back to course
Pdf Summary
Asset Subtitle
Luan Pham
Meta Tag
Speaker Luan Pham
Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2
first-line treatment
advanced stage non-small cell lung cancer
uncommon EGFR mutations
objective response rate
time to treatment failure
adverse events
G719X mutation
dose reduction
Powered By